Plexxikon, Roche File Rx/Dx Application for PLX4032, Cobas Mutation Test in Metastatic Melanoma

Plexxikon is seeking marketing approval for PLX4032 for the treatment of metastatic melanoma in patients harboring the BRAF V600 mutation. Simultaneously, Roche Molecular Diagnostics has submitted a premarket approval application to the FDA for its Cobas 4800 BRAF V600 Mutation Test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.